Carl Zeiss Meditec
Market Cap
€10.8b
Last Updated
2020/10/22 22:01 UTC
Data Sources
Company Financials +
Executive Summary
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with limited growth.
Similar Companies
Share Price & News
How has Carl Zeiss Meditec's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AFX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
2.6%
AFX
-0.3%
DE Medical Equipment
-3.2%
DE Market
1 Year Return
26.9%
AFX
26.4%
DE Medical Equipment
0.2%
DE Market
Return vs Industry: AFX matched the German Medical Equipment industry which returned 26.4% over the past year.
Return vs Market: AFX exceeded the German Market which returned 0.2% over the past year.
Shareholder returns
| AFX | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.6% | -0.3% | -3.2% |
| 30 Day | 21.4% | 8.3% | 1.0% |
| 90 Day | 38.6% | -1.0% | -2.9% |
| 1 Year | 27.8%26.9% | 28.2%26.4% | 3.4%0.2% |
| 3 Year | 175.0%168.3% | 186.5%179.8% | 1.0%-7.8% |
| 5 Year | 379.6%357.6% | 327.7%309.7% | 21.1%3.8% |
Price Volatility Vs. Market
How volatile is Carl Zeiss Meditec's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall St
Has Carl Zeiss Meditec AG's (ETR:AFX) Impressive Stock Performance Got Anything to Do With Its Fundamentals?1 month ago | Simply Wall St
Carl Zeiss Meditec AG's (ETR:AFX) 0.6% Dividend Yield Looks Pretty Interesting1 month ago | Simply Wall St
Are Institutions Heavily Invested In Carl Zeiss Meditec AG's (ETR:AFX) Shares?Valuation
Is Carl Zeiss Meditec undervalued compared to its fair value and its price relative to the market?
91.2x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: AFX (€121.8) is trading above our estimate of fair value (€53.74)
Significantly Below Fair Value: AFX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AFX is poor value based on its PE Ratio (91.2x) compared to the DE Medical Equipment industry average (53.9x).
PE vs Market: AFX is poor value based on its PE Ratio (91.2x) compared to the German market (22.6x).
Price to Earnings Growth Ratio
PEG Ratio: AFX is poor value based on its PEG Ratio (5.4x)
Price to Book Ratio
PB vs Industry: AFX is overvalued based on its PB Ratio (7.5x) compared to the DE Medical Equipment industry average (4.4x).
Next Steps
Future Growth
How is Carl Zeiss Meditec forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
16.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AFX's forecast earnings growth (16.9% per year) is above the savings rate (0.2%).
Earnings vs Market: AFX's earnings (16.9% per year) are forecast to grow slower than the German market (26.7% per year).
High Growth Earnings: AFX's earnings are forecast to grow, but not significantly.
Revenue vs Market: AFX's revenue (7.5% per year) is forecast to grow faster than the German market (6.1% per year).
High Growth Revenue: AFX's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AFX's Return on Equity is forecast to be low in 3 years time (12.7%).
Next Steps
Past Performance
How has Carl Zeiss Meditec performed over the past 5 years?
15.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AFX has high quality earnings.
Growing Profit Margin: AFX's current net profit margins (8.6%) are lower than last year (11.1%).
Past Earnings Growth Analysis
Earnings Trend: AFX's earnings have grown by 15.8% per year over the past 5 years.
Accelerating Growth: AFX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AFX had negative earnings growth (-21.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (14.8%).
Return on Equity
High ROE: AFX's Return on Equity (8.1%) is considered low.
Next Steps
Financial Health
How is Carl Zeiss Meditec's financial position?
Financial Position Analysis
Short Term Liabilities: AFX's short term assets (€1.4B) exceed its short term liabilities (€335.4M).
Long Term Liabilities: AFX's short term assets (€1.4B) exceed its long term liabilities (€265.7M).
Debt to Equity History and Analysis
Debt Level: AFX is debt free.
Reducing Debt: AFX has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.
Debt Coverage: AFX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: AFX has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Carl Zeiss Meditec current dividend yield, its reliability and sustainability?
0.53%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AFX's dividend (0.53%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.22%).
High Dividend: AFX's dividend (0.53%) is low compared to the top 25% of dividend payers in the German market (3.77%).
Stability and Growth of Payments
Stable Dividend: AFX is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: AFX is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: AFX is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AFX's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Ludwin Monz (57 yo)
10.58yrs
Tenure
€1,853,900
Compensation
Dr. Ludwin Monz, Ph.D., M.B.A. has been the Chairman of Management Board at Carl Zeiss Meditec AG since October 8, 2007. Dr. Monz has been the Chief Executive Officer and President of Carl Zeiss Meditec AG ...
CEO Compensation Analysis
Compensation vs Market: Ludwin's total compensation ($USD2.19M) is below average for companies of similar size in the German market ($USD5.28M).
Compensation vs Earnings: Ludwin's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.58yrs | €1.85m | no data | |
| CFO & Member of the Management Board | 2yrs | €855.50k | no data | |
| Head of Surgical Ophthalmology & Member of Management Board | 2yrs | €921.70k | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Head of the Planetarium Business Unit | no data | no data | no data | |
| Head of Marketing - Shanghai | no data | no data | no data | |
| Chief Medical Officer for Global Ophthalmic Devices | 4yrs | no data | no data | |
| Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec | no data | no data | no data | |
| Head of Global Communications Ophthalmic Devices | no data | no data | no data | |
| President of Ophthalmic Devices & Head of the Ophthalmic Devices Strategic Business Unit | 0.42yr | no data | no data |
2.0yrs
Average Tenure
57yo
Average Age
Experienced Management: AFX's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of the Supervisory Board | 0.75yr | no data | no data | |
| Chairman of Supervisory Board | 10.58yrs | €64.00k | no data | |
| Member of the Supervisory Board | 16yrs | €56.00k | no data | |
| Member of the Supervisory Board | 0.75yr | no data | no data | |
| Supervisory Board Member | 1.58yrs | €23.80k | no data | |
| Employee Representative Member of Supervisory Board | 9yrs | €32.00k | no data | |
| Deputy Chairwoman of the Supervisory Board | 2.5yrs | €48.00k | no data | |
| Member of Supervisory Board | 1yr | no data | no data |
2.0yrs
Average Tenure
53yo
Average Age
Experienced Board: AFX's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Carl Zeiss Meditec AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Carl Zeiss Meditec AG
- Ticker: AFX
- Exchange: XTRA
- Founded: 2002
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €10.787b
- Shares outstanding: 89.44m
- Website: https://www.zeiss.com/meditec-ag/home.html
Number of Employees
Location
- Carl Zeiss Meditec AG
- Goschwitzer Strasse 51-52
- Jena
- Thuringia
- 7745
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AFX | DB (Deutsche Boerse AG) | Yes | Bearer Shares | DE | EUR | Mar 2000 |
| AFX | XTRA (XETRA Trading Platform) | Yes | Bearer Shares | DE | EUR | Mar 2000 |
| 0DHC | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | EUR | Mar 2000 |
| CZMW.F | OTCPK (Pink Sheets LLC) | Yes | Bearer Shares | US | USD | Mar 2000 |
| AFXD | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Bearer Shares | GB | EUR | Mar 2000 |
| AFX | SWX (SIX Swiss Exchange) | Yes | Bearer Shares | CH | CHF | Mar 2000 |
| AFX | WBAG (Wiener Boerse AG) | Yes | Bearer Shares | AT | EUR | Mar 2000 |
| AFX | ETLX (Eurotlx) | Yes | Bearer Shares | IT | EUR | Mar 2000 |
| CZMW.Y | OTCPK (Pink Sheets LLC) | UNSPONSORED ADR | US | USD | Oct 2007 | |
| AFXA | DB (Deutsche Boerse AG) | UNSPONSORED ADR | DE | EUR | Oct 2007 |
Biography
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsu ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/22 22:01 |
| End of Day Share Price | 2020/10/22 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.